2 Beaten-Down Dividend Stocks to Buy in 2025

As we enter 2025, investors are looking for undervalued dividend stocks that have the potential to rebound and deliver strong returns. Two beaten-down dividend stocks that fit this description are CVS Health (CVS) and Johnson & Johnson (JNJ). Both companies have faced headwinds in recent years, but their strong fundamentals and attractive valuations make them compelling investment opportunities.

1. CVS Health (CVS)
CVS Health, a leading healthcare services company, has faced challenges in recent years due to lower sales of coronavirus-related products and cost management issues with its Medicare Advantage (MA) plans. However, the company's long-term prospects remain strong, and its dividend is secure. CVS Health has increased its dividend by 90% in the past decade and has a conservative payout ratio of 37.54%. The company's management plans to fix its MA business in 2025, which could improve margins and efficiency. Despite its recent challenges, CVS Health remains a solid income stock to buy in 2025.



2. Johnson & Johnson (JNJ)
Johnson & Johnson, a healthcare giant with a wide economic moat, has faced legal battles related to its talc-based products and potential regulatory changes that could lower drug prices. However, the company's strong balance sheet and history of consistent revenue and profit generation make it a reliable dividend stock. Johnson & Johnson has increased its dividend for 62 consecutive years, with a current payout ratio of 33.48%. Its forward yield is 3.49%, indicating a secure dividend. Investors should monitor the company's legal and regulatory issues, but its dividend growth prospects remain attractive.



In conclusion, CVS Health and Johnson & Johnson are two beaten-down dividend stocks that offer attractive valuations and strong long-term prospects. Despite their recent challenges, both companies have secure dividends and the potential to deliver strong returns in 2025 and beyond. Investors should consider adding these dividend stocks to their portfolios, but it is essential to monitor their progress in addressing their respective issues.